Skip to main content
. 2022 Nov 13;114(2):654–664. doi: 10.1111/cas.15617

FIGURE 2.

FIGURE 2

TAS2940 shows higher selectivity for human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor (EGFR) aberrations. (A) The inhibitory effect of TAS2940 on the phosphorylation of HER2/EGFR in MCF10A cells stably expressing WT or mutant HER2/EGFR. The cells were cultured with TAS2940 or poziotinib and harvested for 4 h following treatment. Phosphorylation of HER2‐Tyr1196 and EGFR‐Tyr1068 was determined by the In‐Cell Western assay. (B) Inhibition of the HER2 signaling pathway and effect of TAS2940, lapatinib, tucatinib, or poziotinib in the SK‐BR‐3 cell line. The cell line was treated by each compound for 3 or 48 h. Phosphorylated HER2, HER3, their downstream signaling factors, or apoptosis markers were detected by western blot analysis. BIM, B‐cell lymphoma 2 interacting mediator of cell death; PARP, poly (ADP‐ribose) polymerase.